Lung Cancer最新文献

英文中文

75 Improving Research Access for Mesothelioma Patients (IRAMP)

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2025-02-01 DOI: 10.1016/j.lungcan.2025.108185

Bolton Simon , Lusted Caitlin , Taylor Bethany , Tod Angela

引用次数: 0

First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis 一线奥西替尼与早期TKIs在晚期egfr突变NSCLC中的比较：现实世界的生存分析

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2025-02-01 DOI: 10.1016/j.lungcan.2025.108084

Igor Gomez-Randulfe , Lauren A. Scanlon , Mathew Carter , Laura Moliner , Emine Cil , Raffaele Califano , Yvonne Summers , Fiona Blackhall , Colin R Lindsay , Jacob Lewis , Fabio Gomes

Objectives

This study aimed to compare the overall survival (OS) of patients with advanced EGFR-mutant NSCLC treated with first-line osimertinib versus earlier-generation EGFR tyrosine kinase inhibitors (TKIs) in a real-world setting. Secondary endpoint included OS in patients with uncommon EGFR mutations. Exploratory aim focused on the impact of TKIs sequencing strategies.

Methods

We conducted a retrospective cohort study of patients diagnosed with advanced EGFR-mutant NSCLC who started first-line treatment with either osimertinib or another EGFR TKI (afatinib, erlotinib, or gefitinib) at The Christie (Manchester, UK) from January 2014 to May 2023. Data were extracted from electronic health records, and survival outcomes were analysed using Kaplan-Meier estimates and Cox proportional hazards models.

Results

We identified 119 patients treated with first-line osimertinib and 217 with other EGFR TKIs. In the whole population, median age was 69 years (IQR 59.8–77) and 67.3 % of the patients had an ECOG 0–1. With a median follow-up of 73.2 months (95 % CI 66.2–115.7) and 30.6 months (95 % CI 26.0–38.4) in the earlier-generation TKIs and the osimertinib groups, respectively, the median OS was comparable (16.6 vs 16.9 months; HR = 1, p = 0.97). Patients with uncommon EGFR mutations (n = 48; 14.3 %) had poorer survival compared to those with common mutations (HR = 1.664, p = 0.002). Amongst patients who received two treatment lines, those who received osimertinib after another TKI had a shorter OS than those who received osimertinib first-line followed by another line of therapy (HR = 2.062, p = 0.022).

Conclusion

First-line osimertinib showed comparable OS to earlier-generation EGFR TKIs for advanced EGFR-mutant NSCLC. Patients with uncommon EGFR mutations had a poorer survival. Further research is warranted to optimize treatment for patients with uncommon EGFR mutations and to explore the cost-effectiveness of different sequencing approaches.

目的：本研究旨在比较一线奥西替尼与早期EGFR酪氨酸激酶抑制剂（TKIs）治疗的晚期EGFR突变NSCLC患者的总生存期（OS）。次要终点包括罕见EGFR突变患者的OS。探索性目的集中于TKIs测序策略的影响。方法：我们对2014年1月至2023年5月在英国曼彻斯特克里斯蒂医院（The Christie）接受奥西替尼或另一种EGFR TKI（阿法替尼、厄洛替尼或吉非替尼）一线治疗的晚期EGFR突变NSCLC患者进行了一项回顾性队列研究。从电子健康记录中提取数据，并使用Kaplan-Meier估计和Cox比例风险模型分析生存结果。结果：我们确定了119例接受一线奥西替尼治疗的患者和217例接受其他EGFR TKIs治疗的患者。在整个人群中，中位年龄为69岁（IQR 59.8-77）， 67.3%的患者ECOG为0-1。早期tki组和奥西替尼组的中位随访时间分别为73.2个月（95% CI 66.2-115.7）和30.6个月（95% CI 26.0-38.4），中位OS是相当的(16.6个月vs 16.9个月；HR = 1, p = 0.97)。罕见EGFR突变患者(n = 48；14.3%)的患者生存率较普通突变患者低（HR = 1.664, p = 0.002）。在接受两条治疗线的患者中，第一次TKI后接受奥西替尼治疗的患者的OS比第一次接受奥西替尼治疗后再接受另一条治疗的患者的OS短（HR = 2.062, p = 0.022）。结论：一线奥西替尼治疗晚期EGFR突变型NSCLC的OS与早期EGFR TKIs相当。具有罕见EGFR突变的患者生存率较低。需要进一步的研究来优化对罕见EGFR突变患者的治疗，并探索不同测序方法的成本效益。

{"title":"First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis","authors":"Igor Gomez-Randulfe , Lauren A. Scanlon , Mathew Carter , Laura Moliner , Emine Cil , Raffaele Califano , Yvonne Summers , Fiona Blackhall , Colin R Lindsay , Jacob Lewis , Fabio Gomes","doi":"10.1016/j.lungcan.2025.108084","DOIUrl":"10.1016/j.lungcan.2025.108084","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to compare the overall survival (OS) of patients with advanced EGFR-mutant NSCLC treated with first-line osimertinib versus earlier-generation EGFR tyrosine kinase inhibitors (TKIs) in a real-world setting. Secondary endpoint included OS in patients with uncommon EGFR mutations. Exploratory aim focused on the impact of TKIs sequencing strategies.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of patients diagnosed with advanced EGFR-mutant NSCLC who started first-line treatment with either osimertinib or another EGFR TKI (afatinib, erlotinib, or gefitinib) at The Christie (Manchester, UK) from January 2014 to May 2023. Data were extracted from electronic health records, and survival outcomes were analysed using Kaplan-Meier estimates and Cox proportional hazards models.</div></div><div><h3>Results</h3><div>We identified 119 patients treated with first-line osimertinib and 217 with other EGFR TKIs. In the whole population, median age was 69 years (IQR 59.8–77) and 67.3 % of the patients had an ECOG 0–1. With a median follow-up of 73.2 months (95 % CI 66.2–115.7) and 30.6 months (95 % CI 26.0–38.4) in the earlier-generation TKIs and the osimertinib groups, respectively, the median OS was comparable (16.6 vs 16.9 months; HR = 1, p = 0.97). Patients with uncommon EGFR mutations (n = 48; 14.3 %) had poorer survival compared to those with common mutations (HR = 1.664, p = 0.002). Amongst patients who received two treatment lines, those who received osimertinib after another TKI had a shorter OS than those who received osimertinib first-line followed by another line of therapy (HR = 2.062, p = 0.022).</div></div><div><h3>Conclusion</h3><div>First-line osimertinib showed comparable OS to earlier-generation EGFR TKIs for advanced EGFR-mutant NSCLC. Patients with uncommon EGFR mutations had a poorer survival. Further research is warranted to optimize treatment for patients with uncommon EGFR mutations and to explore the cost-effectiveness of different sequencing approaches.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108084"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adherence to community-based lung cancer screening in the Yorkshire Lung Screening Trial

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2025-02-01 DOI: 10.1016/j.lungcan.2025.108086

Sarah Q. Ahmad , Francesca Pesola , Philip A.J. Crosbie , Rhian Gabe , Neil Hancock , Martyn P.T. Kennedy , Catriona Marshall , Samantha L. Quaife , Suzanne Rogerson , Irene Simmonds , Matthew E.J. Callister

Introduction

Lung cancer screening saves lives by detecting cancers early, but continued adherence to screening rounds is required for participants to experience the maximum clinical benefit. Here we describe factors associated with screening adherence in the Yorkshire Lung Screening Trial.

Methods

All eligible individuals following baseline (prevalent) screening were invited for a biennial incident screen in a community setting. Participants were contacted by phone (up to two attempts) to arrange an appointment or sent a pre-arranged appointment letter if non-contactable. Characteristics of attenders versus non-attenders were compared using univariate and multivariable models.

Results

Of 6,650 individuals who attended baseline screening, 5,975 were eligible for the second round. The mean age of those eligible was 70.5 years, 45.2 % were female, 31.7 % were from the most socio-economically deprived quintile and 33.9 % reported current smoking at the time of the baseline scan. Of these, 5,184 (86.8 %) attended their second screen and 791 (13.2 %) did not. Factors associated with lower attendance following multivariable analysis were socio-economic deprivation (OR 0.78, 95 % CI 0.60–1.02, most versus least deprived quintile) and current smoking (OR 0.57, 95 % CI 0.48–0.66, current versus previously quit). Sex, age, and ethnicity were not associated with attendance. Attendance was more likely in people who had an indeterminate (OR 2.10, 95 % CI 1.61–2.73; n = 871) or positive (OR 3.16, 95 % CI 0.98–10.19; n = 60) baseline scan compared to a negative baseline scan.

Discussion

Adherence was good overall but lower adherence amongst people who currently smoke and those from deprived populations is a concern due to their greater risk of lung cancer death. Further research is needed into interventions that increase adherence in these high-risk populations.

{"title":"Adherence to community-based lung cancer screening in the Yorkshire Lung Screening Trial","authors":"Sarah Q. Ahmad , Francesca Pesola , Philip A.J. Crosbie , Rhian Gabe , Neil Hancock , Martyn P.T. Kennedy , Catriona Marshall , Samantha L. Quaife , Suzanne Rogerson , Irene Simmonds , Matthew E.J. Callister","doi":"10.1016/j.lungcan.2025.108086","DOIUrl":"10.1016/j.lungcan.2025.108086","url":null,"abstract":"<div><h3>Introduction</h3><div>Lung cancer screening saves lives by detecting cancers early, but continued adherence to screening rounds is required for participants to experience the maximum clinical benefit. Here we describe factors associated with screening adherence in the Yorkshire Lung Screening Trial.</div></div><div><h3>Methods</h3><div>All eligible individuals following baseline (prevalent) screening were invited for a biennial incident screen in a community setting. Participants were contacted by phone (up to two attempts) to arrange an appointment or sent a pre-arranged appointment letter if non-contactable. Characteristics of attenders versus non-attenders were compared using univariate and multivariable models.</div></div><div><h3>Results</h3><div>Of 6,650 individuals who attended baseline screening, 5,975 were eligible for the second round. The mean age of those eligible was 70.5 years, 45.2 % were female, 31.7 % were from the most socio-economically deprived quintile and 33.9 % reported current smoking at the time of the baseline scan. Of these, 5,184 (86.8 %) attended their second screen and 791 (13.2 %) did not. Factors associated with lower attendance following multivariable analysis were socio-economic deprivation (OR 0.78, 95 % CI 0.60–1.02, most versus least deprived quintile) and current smoking (OR 0.57, 95 % CI 0.48–0.66, current versus previously quit). Sex, age, and ethnicity were not associated with attendance. Attendance was more likely in people who had an indeterminate (OR 2.10, 95 % CI 1.61–2.73; n = 871) or positive (OR 3.16, 95 % CI 0.98–10.19; n = 60) baseline scan compared to a negative baseline scan.</div></div><div><h3>Discussion</h3><div>Adherence was good overall but lower adherence amongst people who currently smoke and those from deprived populations is a concern due to their greater risk of lung cancer death. Further research is needed into interventions that increase adherence in these high-risk populations.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108086"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2025-02-01 DOI: 10.1016/j.lungcan.2025.108101

Joshua E. Reuss , Jacob Zaemes , Nishant Gandhi , Phillip Walker , Sandip P. Patel , Joanne Xiu , Charu Aggarwal , Ari Vanderwalde , Suresh S. Ramalingam , Balazs Halmos , Stephen V. Liu

Background

Next-generation sequencing (NGS) to detect actionable genomic driver alterations (AGAs) is critical to appropriate management of non-small cell lung cancer (NSCLC), but is inconsistently performed for squamous NSCLC (sqNSCLC). Molecular characterization of sqNSCLC by smoking status has not been well-reported. We analyzed a large cohort of sqNSCLC utilizing NGS to elucidate molecular differences in sqNSCLC by smoking status.

Methods

sqNSCLC was profiled by NGS using a 592 gene panel. Smoking status was obtained from medical records. Genomic alterations, mutation burden, PD-L1 immunohistochemistry, gene set enrichment analyses (GSEA), immune-cell infiltration, and clinical outcomes were compared between never- and ever-smokers. Fisher’s exact, Mann-Whitney U or t-tests were used, where appropriate. Statistical significance was defined as p < 0.05 with q < 0.05 or FDR < 0.25, where appropriate.

Results

2,891 patients with sqNSCLC were included, of which 2862 (98%) were ever-smokers and 63 (2%) were never-smokers. AGAs were detected in 22.2% (14/63) of never-smokers and 2.4% (69/2828) of ever-smokers. Never-smokers had a significantly higher prevalence of actionable MET and EGFR mutations compared to ever-smokers (9.5% vs 0.4% and 7.9% vs 0.4%, respectively), though actionable alterations were detected in both cohorts. GSEA revealed significantly enriched expression of interferon-α, interferon-γ and IL-6/JAK/STAT pathways in never-smokers.

Conclusion

A high frequency of AGAs were detected in never-smokers with sqNSCLC, with significantly increased prevalence of actionable EGFR and MET alterations compared to ever-smokers. Our findings indicate that, analogous to the diagnostic algorithm for non-squamous NSCLC, NGS testing to inform frontline treatment decision-making is critical for never-smokers with sqNSCLC.

{"title":"Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking","authors":"Joshua E. Reuss , Jacob Zaemes , Nishant Gandhi , Phillip Walker , Sandip P. Patel , Joanne Xiu , Charu Aggarwal , Ari Vanderwalde , Suresh S. Ramalingam , Balazs Halmos , Stephen V. Liu","doi":"10.1016/j.lungcan.2025.108101","DOIUrl":"10.1016/j.lungcan.2025.108101","url":null,"abstract":"<div><h3>Background</h3><div>Next-generation sequencing (NGS) to detect actionable genomic driver alterations (AGAs) is critical to appropriate management of non-small cell lung cancer (NSCLC), but is inconsistently performed for squamous NSCLC (sqNSCLC). Molecular characterization of sqNSCLC by smoking status has not been well-reported. We analyzed a large cohort of sqNSCLC utilizing NGS to elucidate molecular differences in sqNSCLC by smoking status.</div></div><div><h3>Methods</h3><div>sqNSCLC was profiled by NGS using a 592 gene panel. Smoking status was obtained from medical records. Genomic alterations, mutation burden, PD-L1 immunohistochemistry, gene set enrichment analyses (GSEA), immune-cell infiltration, and clinical outcomes were compared between never- and ever-smokers. Fisher’s exact, Mann-Whitney U or t-tests were used, where appropriate. Statistical significance was defined as p < 0.05 with q < 0.05 or FDR < 0.25, where appropriate.</div></div><div><h3>Results</h3><div>2,891 patients with sqNSCLC were included, of which 2862 (98%) were ever-smokers and 63 (2%) were never-smokers. AGAs were detected in 22.2% (14/63) of never-smokers and 2.4% (69/2828) of ever-smokers. Never-smokers had a significantly higher prevalence of actionable <em>MET</em> and <em>EGFR</em> mutations compared to ever-smokers (9.5% vs 0.4% and 7.9% vs 0.4%, respectively), though actionable alterations were detected in both cohorts. GSEA revealed significantly enriched expression of interferon-α, interferon-γ and IL-6/JAK/STAT pathways in never-smokers.</div></div><div><h3>Conclusion</h3><div>A high frequency of AGAs were detected in never-smokers with sqNSCLC, with significantly increased prevalence of actionable <em>EGFR</em> and <em>MET</em> alterations compared to ever-smokers. Our findings indicate that, analogous to the diagnostic algorithm for non-squamous NSCLC, NGS testing to inform frontline treatment decision-making is critical for never-smokers with sqNSCLC.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108101"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143101905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

52 Lung Cancer Triage Process: Identifying referrals who are less likely to have cancer and triaging patients for ‘Straight to Test’ CT scans and the effect on Clinic Availability

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2025-02-01 DOI: 10.1016/j.lungcan.2025.108162

Taylor Rebecca , Dunnett Timothy , Dickson Matthew , Hashim Mohammed , Durham Lindsay , Smith Leigh , Chamberlin Naomi

引用次数: 0

10 Reporting of central airways obstruction

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2025-02-01 DOI: 10.1016/j.lungcan.2025.108121

Pearce Catharine , Crowle Daniel , Thorley Richard , Marchbank Adrian , Riordan Richard , Daneshvar Cyrus

引用次数: 0

14 Thymic pathologies conundrum requires establishment of a Central MDT

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2025-02-01 DOI: 10.1016/j.lungcan.2025.108125

Mazcuri Misauq , Kalkat Maninder , Jegannathen Apurna , Middleton Gary , Srinivasan Lakshmi , Fallouh Hazem , Morgan Jacqui , Naidu Babu , Oiley Ahmed , Stevenson Robert , Abid Ambreen , Al-Haddi Salah

引用次数: 0

59 The clinical utility of liquid biopsy in patients with advanced non-small cell lung cancer in Newcastle

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2025-02-01 DOI: 10.1016/j.lungcan.2025.108169

Jinga Maria-Ruxandra , Hall Sally , Gardiner Jill , Rushton Christine , Singh Samanjay , Stonebanks Victoria , Anderson Victoria , Harris David , English Hayley , Ward Ann , Hayhurst Hannah , Elgendy Manal , Greystoke Alastair

引用次数: 0

83 Durvalumab in Locally Advanced Unresectable Non-Small-Cell Lung Cancer – Benchmarking Real-World Outcomes in England Against Published Trial Data

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2025-02-01 DOI: 10.1016/j.lungcan.2025.108193

Webster Laura , Tokaca Nadza , Thackray Katherine , Kipps Emma , Clarke Peter , Lawton Sarah

引用次数: 0

60 Physician led focused neck ultrasound and cervical lymph node sampling: a survey of lung cancer physicians

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2025-02-01 DOI: 10.1016/j.lungcan.2025.108170

Thorley Richard , Pearce Catharine , Breen David , Daneshvar Cyrus , Hassan Maged

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Lung Cancer

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀